trending Market Intelligence /marketintelligence/en/news-insights/trending/_GyIQlQOetLsKZK8hWqXbg2 content esgSubNav
In This List

US FDA amends target action date for Clinuvel's photosensitivity drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA amends target action date for Clinuvel's photosensitivity drug

Clinuvel Pharmaceuticals Ltd. said the U.S. Food and Drug Administration verified that the target action date for its drug Scenesse is Oct. 8, not Oct. 6 as earlier announced.

Scenesse, or afamelanotide, is a potential treatment for a rare metabolic disorder known as erythropoietic protoporphyria, or EPP. The condition is characterized by photosensitivity, in which sun exposure causes itching, reddening, swelling, pain and even burns.

The regulator clarified that the previous Prescription Drug User Fee Act, or PDUFA, goal date was miscommunicated.

The original PDUFA date for the company's application was July 6. However, the FDA extended the review period in June, citing the need for more time to complete a full review of the application.

Clinuvel's chief scientific officer, Dennis Wright, said the revised PDUFA date has no material change in the company's outlook.

Scenesse received orphan-drug and fast-track status from the FDA in 2008 and 2016, respectively. The drug, which Clinuvel evaluated in five clinical trials, is approved in Europe to prevent phototoxicity in EPP patients.